Location: Oxford or London (Hybrid)

The Mission: Why We Exist

Genomics is a science-led transatlantic TechBio combining large-scale genetic and health data with proprietary analytics to accelerate drug discovery and advance predictive, preventative healthcare. We are united by a single vision to help people live longer healthier lives, using the power of genomics.

Genomics aims to help people live longer, healthier lives in two ways: super-charging drug discovery and development for novel treatments with our AI-enabled advanced genetic analytics platform, and by helping people understand their personal risk of common chronic diseases through polygenic risk scores - giving doctors and health systems the chance to get the right people into the right prevention, screening and treatment programmes at the right time.

Role Purpose

Genomics runs on multi-trillion-row, petabyte-scale genetic and health data. Mystra is the analytical data platform that makes that usable, and MystraAI is the agentic layer we're building on top of it. This is a Staff-level role for someone who wants to push the boundaries of what a data platform can do — solving hard, novel infrastructure problems at genuine scale, and setting the technical direction that other teams build on.

You'll lead the analytical data platform and our Data-as-a-Service offering, shape the data foundations behind MystraAI, and line-manage a small team of engineers while staying deeply hands-on. If you want your work to sit at the intersection of large-scale systems engineering and genuinely meaningful science, this is it.

A Day in the Life

The role spans the full depth of the platform — from database internals up to the systems that serve data across the product. On any given day you might be:

Pushing multi-tenant ClickHouse (or equivalent OLAP) clusters to their limits at multi-trillion-row, petabyte scale — designing sharding and replication strategies, building materialised views, and solving genuinely hard performance and cost/efficiency problems most engineers never get to touch.
Building the tooling and automation that lets data-intensive pipelines scale themselves — smart observability, predictive capacity planning, and systems resilient enough that incidents become rare rather than routine.
Shaping Data-as-a-Service as a real product — designing a secure, multi-tenant, immutable release architecture, with data made discoverable at scale through catalogue and ontology-driven search, in partnership with the data team.
Powering agentic AI from the data platform — architecting the data foundations behind MystraAI and designing secure, tenant-scoped access patterns for autonomous agents, partnering closely with the ML team on how our AI systems perform.
Treating security as a design problem, not a checklist — building tenant isolation, credential management and least-privilege access into the architecture from first principles.
Setting technical direction, mentoring engineers, and influencing decisions well beyond your own team.

Who You Are

You're a recognised specialist who leads through expertise — principal-level individual-contributor depth combined with the judgement to set standards others follow. You'll bring:

Large-scale OLAP / ClickHouse. Deep experience designing and pushing multi-tenant ClickHouse at extreme scale. You engage with the engine at source level rather than as a black box — and ideally have contributed code upstream.
Platform engineering at scale. You've built self-healing, observable systems for analytical data platforms and pipelines — the kind of engineering that reduces toil rather than manages it.
Data-as-a-Service productisation. You think in terms of data as a product: secure, multi-tenant, immutable releases, and discoverability at scale.
Agent-ready data. You understand what it takes to expose platform data to agents safely and at scale — access patterns, tenant isolation, sensible guardrails — and have scaled data infrastructure under demanding workloads.
Multi-tenant security. You design for isolation, least-privilege access and sound secrets management from the outset.
Technical leadership. You drive direction and innovation across a platform, mentor engineers, and can line-manage a small team without losing your own hands-on edge.

Your Package

We are committed to providing a transparent, supportive, and rewarding work environment.

Compensation & Growth

Competitive Salary: Salaries are externally benchmarked annually to ensure top-of-market compensation.
Clear Career Path: A straightforward, open progression framework means you'll always know the path to promotion and how to achieve your next career goal.
Continuous Learning: Including external courses and a wide library of L&D materials, because your growth is our success.

Wellbeing & Time Off

Holiday: 25 days annual leave, plus bank holidays, plus an extra 3-day company-wide shutdown at year-end.
Financial & Health Security: Robust benefits including a market-leading pension scheme, comprehensive private health insurance for you and your family with NO excess, critical illness, and life assurance.
Enhanced Leave: Enhanced paid family leave to support all new parents.

Work Environment & Culture

Flexible Working: Hybrid Working (e.g., From our London, Oxford Office)
Truly Inclusive Time Off: Our 'Bank Your Bank Holiday' program allows you to exchange public holidays for dates that hold personal or cultural significance to you.
Vibrant Social Culture: From regular Town Halls and team picnics to organised sports events, our social committee ensures frequent opportunities to connect and celebrate.
Green Commute: Cycle-to-Work scheme and convenient office locations near major transport hubs.

Ready to Build the Future?

If this opportunity excites you, apply now!

We are dedicated to creating a diverse environment and are proud to be an equal-opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.

Genomics politely requests no contact from recruitment agencies. We do not accept speculative CVs from recruitment agencies nor accept the fees associated with them.

About the company

Genomics plc uses genomic data to improve health care and drug discovery. It analyzes patients' genetic information to generate insights about biology and disease and then integrates these findings into clinical practice and research. The company partners with healthcare systems, pharmaceutical companies, providers, and payers to apply genomics to personalized medicine, helping doctors select better treatments and accelerating the development of new drugs. Its offerings include data-driven analytics and decision-support that embed genomic information into clinical and research workflows. Genomics plc differentiates itself by pursuing wide-ranging collaborations across the healthcare ecosystem to turn genomic data into practical, real-world decisions. The goal is to enable longer, healthier lives by making care and therapy choices more precise through genomics.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$136M

Headquarters

Oxford, United Kingdom

Founded

2014

Get referred to Genomics

See people who can refer or advise you

Simplify's Take

What believers are saying

Mystra AI launched June 2026 with Novo Nordisk, BridgeBio, and Relation Therapeutics adoption.
Greywolf partnership on April 29, 2026 expands autoimmune target-validation work immediately.
London flagship office opened February 2026, signaling hiring, sales expansion, and customer access.

What critics are saying

Vertex expires in 2026, exposing revenue if renewal terms weaken or lapse.
Novo Nordisk and BridgeBio can internalize genetics workflows, compressing Genomics' pricing power.
If Mystra underdelivers, pharma shifts to in-house platforms and Genomics becomes a services shop.

What makes Genomics unique

Genomics' 45,000 GWAS and trillions of rows create unmatched genotype-phenotype depth.
Mystra AI turns human genetics queries into instant, traceable target-validation outputs.
Over 60 statistical geneticists let Genomics deliver managed collaborations beyond software.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Pension scheme
Flexible Working?
Hybrid Work Options
Holiday: 25 days annual leave, plus bank holidays, plus an extra 3-day company-wide shutdown at year-end
Wellness Program
Mental Health Support
Family Planning Benefits

Growth & Insights and Company News

6 month growth

-2%

1 year growth

2 year growth

PR Newswire

Jun 2nd, 2026

Genomics launches Mystra AI platform to accelerate drug discovery with world's largest genetics database

Genomics has launched Mystra AI, a conversational AI platform for drug target discovery and validation, now adopted by pharmaceutical giants including Novo Nordisk and biotechs like BridgeBio Pharma and Relation Therapeutics. The platform leverages Genomics' proprietary database containing over 45,000 genome-wide association studies and trillions of data rows—the world's largest genotype-phenotype collection. With 95% of drug candidates failing in clinical trials, Mystra AI addresses this by focusing on genetically-supported targets, which are 2.6 times more likely to succeed. Mystra AI allows scientists to query the database using plain language, providing transparent, verifiable genetic insights for target discovery and validation. The platform offers three engagement models: self-service access, partly managed for proprietary data integration, and fully managed collaboration with Genomics' team of over 60 statistical geneticists.

AllSci

Apr 30th, 2026

Greywolf and Genomics partner to develop first-in-class ERAP autoimmune disease treatments.

Greywolf and Genomics partner to develop first-in-class ERAP autoimmune disease treatments. April 30, 2026 UK-based Greywolf Therapeutics and Genomics have announced a strategic research collaboration to apply large-scale human genetic data to the development of ERAP autoimmune disease treatments, with Genomics deploying its proprietary genotype-phenotype platform to validate ERAP1 and ERAP2 as therapeutic targets across multiple autoimmune indications and guide Greywolf's pipeline expansion strategy. Under the agreement, Genomics will curate and analyze multiple independent genetic association studies drawn from what the company describes as the world's largest harmonized genotype-phenotype data resource, with the objective of identifying which specific ERAP1 ERAP2 genetic variants drive disease susceptibility across conditions including inflammatory bowel disease, ankylosing spondylitis, and psoriasis. The resulting insights will inform Greywolf's indication selection and patient stratification strategy for its ERAP-targeting small molecule pipeline, with GRWD0715 currently progressing in a Phase I/II trial in axial spondyloarthritis. Financial terms were not disclosed. Greywolf's development program centers on antigen modulation - specifically the control of T cell activation through modulation of antigen presentation via the MHC class I pathway. ERAP1 and ERAP2 are aminopeptidases responsible for trimming peptides prior to loading onto MHC class I molecules; genetic variants in both enzymes alter the antigenic peptide repertoire presented to the immune system, and have been shown through genome-wide association studies to increase susceptibility to a range of autoimmune conditions. Greywolf's first-in-class autoimmune treatment approach targets this mechanism directly, with GRWD0715 designed to correct aberrant antigen presentation rather than broadly suppress immune function. The collaboration addresses a specific technical challenge in ERAP-focused immunotherapy drug development: ERAP1 and ERAP2 are highly polymorphic, with multiple functionally distinct haplotypes that produce different enzymatic activities across human populations. Standard preclinical models cannot capture this complexity, making human genetic evidence the most reliable basis for both target validation and indication prioritization. Genomics' platform applies statistical genetics methods including Mendelian randomization and colocalization analysis to biobank-scale datasets, enabling causal inference at the variant level rather than relying on aggregate association signals. Genomics, spun out of the University of Oxford in 2014, has built its platform over a decade of statistical and human genetics research. The company's CEO and co-founder, Professor Sir Peter Donnelly, previously directed the Wellcome Centre for Human Genetics at Oxford, where his group conducted genome-wide association studies that identified ERAP1 and ERAP2 as autoimmune disease risk genes. That scientific history positions Genomics as a particularly direct fit for this program, given that the foundational genetic evidence underpinning Greywolf's target selection originated in part from the same institution. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked *

BioWorld

Apr 30th, 2026

Genomics and greywolf partner in autoimmune diseases.

Genomics and greywolf partner in autoimmune diseases. April 30, 2026 Genomics Ltd. has established a strategic relationship with Grey Wolf Therapeutics Ltd. (Greywolf) to develop first-in-class treatments for autoimmune diseases.

GenomeWeb

Mar 12th, 2026

Genomics Ltd., BioMarin Pharmaceutical Partner on Rare Disease Research

Genomics Ltd., BioMarin Pharmaceutical partner on rare disease research. NEW YORK - Genomics Ltd. on Thursday announced an ongoing partnership with BioMarin Pharmaceutical to advance rare disease drug discovery and development. To read the full story...

Boone Newspapers Inc.

Oct 16th, 2025

Genomics launches Mystra: the world's first and original AI-enabled human genetics platform, now available to transform drug target discovery and clinical development

Genomics launches Mystra: the world's first and original AI-enabled human genetics platform, now available to transform drug target discovery and clinical development. The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights and, therefore, the probability of honing in on successful drug candidates BOSTON, Oct. 16, 2025 /PRNewswire/ - Genomics, a science-led techbio company using large-scale genetic information to develop innovative precision healthcare tools and to accelerate drug discovery and development, has today announced the launch of Mystra, the world's original AI-enabled human genetics platform designed to supercharge drug target discovery and validation. The platform was officially announced during a Genomics presentation at the American Society of Human Genetics 2025 in Boston. The pharmaceutical industry faces a significant research and development (R&D) productivity crisis, with the failure rate for drug candidates in clinical trials soaring to 95%. This rate pushes the average cost of bringing a new medicine to market beyond $2.3 billion, leading to unsustainable pricing and restricted patient access to life-saving treatments. Genomics is addressing this challenge by equipping researchers with a powerful solution built on the fact that targets with human genetic support are 2.6 times more likely to succeed in clinical trials. Over the last 10 years, Genomics has ingested, harmonized, and quality-controlled what is now the world's largest and most diverse human genotype-phenotype database. The new platform builds on and augments these datasets, providing extensive, powerful insights into human biology, with relevant information for drug development and critical insights into disease mechanisms supported by evidence from studies of genetic variation. Enabled by proprietary AI and advanced algorithms, Genomics' Foundational Data Collection encompasses over 20,000 genome-wide associated studies (GWAS) and trillions of rows of data. Mystra harnesses world-leading algorithms, providing users with critical insights into disease mechanisms supported by evidence from studies of genetic variation. Augmented with cutting-edge machine learning tools, this platform delivers rapid, deep analyses necessary for drug development. Human genetics teams currently spend excessive time managing fragmented, siloed datasets and running manual analyses. Insights are often generated too late to meaningfully influence early discovery or clinical strategy. Collaboration across biology, chemistry, and clinical teams is slow as data and tools are not integrated. This can now change with Mystra. Mystra turns human genetics from a slow, fragmented, specialist-driven process into a high-speed, integrated capability that informs drug discovery and development. By unifying genomic data, analysis tools, and collaboration capabilities in one platform, it makes genetics teams dramatically more productive - so they can spend time on insight generation, not data cleanup. It enables earlier, stronger decision-making in target identification, validation, and clinical trial design, and it connects cross-functional teams with a shared source of truth for genetic evidence. Mystra is the culmination of a decade-long effort, providing a secure, scalable, and intuitive platform that allows users to: * Build Genetic Conviction: Instantly assess the efficacy and safety of drug candidates against the world's most comprehensive human genetic evidence. * Accelerate R&D: Turn complex genetic analysis queries that historically took months into results in a matter of minutes. * De-Risk Investment: Increase the probability of success for every drug candidate by helping choose better drug candidates, resulting in higher-quality assets entering the pipeline. Genomics' own use of the platform is expected to contribute dozens of targets to pharma R&D pipelines this year alone. "For over a decade, we have been meticulously building and using an unparalleled platform of genetic insights to accelerate our own collaborations with biopharma partners," said Dave Thornton, President, Genomics. "Today, we are making this breakthrough technology available to the statistical geneticists throughout the R&D community. Mystra transforms fragmented data into actionable, high-conviction insights, empowering statistical geneticists and life sciences companies to make real-time decisions that were previously impossible. We are changing the trajectory of drug development - to bring tomorrow's medicine for the patients of today, safer and faster." The platform will be the first ever fully scalable solution available to life sciences companies for the use of multi-omic data for R&D. Omics data is heterogeneous and requires specialist expertise and complex methods to harmonize, analyze, and extract meaningful and actionable insights. Pharmaceutical and biotech partners can access Mystra's unmatched scale and analytical power through flexible engagement models: * Self-service (SaaS): Enroll teams for direct access to Mystra, leveraging the platform's proprietary datasets and analysis tools. * Partly Managed: Bring proprietary internal data to securely combine it with Genomics' world-leading datasets for bespoke analysis. * Fully Managed: Collaborate with Genomics' team of over 60 statistical genetic scientists - one of the largest in Europe - to supercharge pipelines and accelerate breakthroughs. Mystra is already being used by several of the world's largest pharmaceutical companies in an early-access program. Looking ahead, it will continue to expand its multi-modal capabilities, ensuring it becomes an integral platform empowering every scientist across the discovery and development journey. For more information and to explore the platform, visit mystra.com. For more information about Genomics, visit genomics.com. About Genomics Genomics is a pioneering science-led techbio company that uses large-scale genetic information to develop innovative precision healthcare tools and bring new understanding to drug discovery. Valley Times-News were formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford. Today, Valley Times-News is collaborating with some of the world's leading healthcare organisations and helping them to predict, prevent, treat, and cure - dramatically reducing the human and financial cost of common diseases like cancer, diabetes, and heart disease. View original content to download multimedia:https://www.prnewswire.com/news-releases/genomics-launches-mystra-the-worlds-first-and-original-ai-enabled-human-genetics-platform-now-available-to-transform-drug-target-discovery-and-clinical-development-302586011.html SOURCE Genomics

Genomics

Product Engineer

About the job